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ESUR guidelines for MR imaging
of the sonographically indeterminate adnexal
mass: an algorithmic approach
Abstract A significant proportion of
adnexal masses detected by sonogra-
phy are indeterminate. Either their
organ of origin is uncertain or it is
unclear whether their nature is benign
or malignant. MR imaging of the
sonographically indeterminate adnex-
al mass can resolve most of these
uncertainties. Most indeterminate
masses result from common benign
conditions and women with such
masses can avoid unnecessary or
inappropriate surgery. For the minor-
ity of women whose masses are ma-
lignant, use of MR imaging rather than
a ‘wait and watch’ strategy of repeat
ultrasound (US) results in a more
timely diagnosis. There are simple
diagnostic steps in the MR imaging
assessment which direct an algorith-
mic and problem-solving approach
based on signal characteristics and
morphology. MR imaging should
provide a more timely diagnosis and,
thereby, guide the management of the
patient with reduced costs of investi-
gation and treatment.
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Introduction
Ultrasound (US) is the first-line imaging study of women
clinically suspected to have an adnexal mass [1].
Combined with clinical assessment and consideration of
the serum level of CA-125, US is used to place adnexal
masses into one of three categories which define further
investigation and management:
. A benign mass
. A malignant mass with or without signs of peritoneal
metastasis
. An indeterminate mass
The sonographically (US) indeterminate adnexal mass is
defined as one which has complexity but which, after
thorough interrogation including Doppler assessment, can-
not be confidently placed into either the benign or malignant
category; or one for which the site of origin, from the ovary,
uterus or another pelvic structure remains to be established.
Adnexal masses are increasingly discovered in the investig-
ation of other abdominal and pelvic problems as cross-
sectional imaging has supplanted contrast studies of the
genitourinary and gastrointestinal tract (e.g. CT colonography
and urography, unenhanced CT for detection of urinary
calculi) [2–4]. Such incidental findings result in further utili-
sation of imaging to allay patient and physician anxiety about
their nature with significant economic consequences [3].
The clinical impact of defining whether an indeterminate
mass is benign or malignant is enormous. Women with
malignant adnexal masses require radical cytoreductive sur-
gery by a specialist surgeon with expertise in gynaecological
oncology [5–7], whilst benign masses may be either managed
conservatively or undergo resection under the care of a general
gynaecologist. Further, women with suspected malignancy
may require transfer of their care to a specialist institution.
It is no longer appropriate for women with indeterminate
masses to undergo exploratory surgery without clear and
directed therapeutic intent. For women with these inde-
terminate masses MR imaging has the capability to:
. Reduce the number undergoing unnecessary surgery
for benign lesions—‘overoperation’
. Reduce the risk of missing malignant lesions—
‘underoperation’
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The majority of sonographically (US) indeterminate
masses are not rare and exotic lesions but common
adnexal lesions [8, 9] such as mature teratomas (dermoid
tumours) with minimal fat or other atypical features,
haemorrhagic lesions in which adherent blood clot may
mimic mural vegetations and solid fibrous masses (ovarian
fibroma/thecoma and uterine leiomyomata) whose solid
nature raises concerns for malignancy. Thus most
indeterminate adnexal masses are actually complex benign
lesions. Even with application of exemplary MR imaging
technique some masses remain indeterminate in nature. It
is usual to report such masses as probably malignant.
However, the proportion of sonographically indeterminate
adnexal masses ‘overcalled’ as malignant falls dramati-
cally after MR imaging. Less than one in ten indeterminate
masses are ‘overcalled’ by the combination of US
followed by MR imaging [8].
There is heterogeneity in this group of indeterminate
lesions and a single diagnostic imaging protocol is less
easy to define than for other recognised applications of
gynaecological MR imaging e.g. for staging malignancy
when both the site and histology of disease has already
been defined. It is for this reason that the European Society
of Urogenital Radiology (ESUR) Female Imaging Sub-
Committee has discussed and developed an algorithmic
approach to the MR imaging assessment of the US
indeterminate mass.
Process
These guidelines were developed by consensus, based on
expert opinion and following review of current practice
across senior members of ESUR. Following a review of
then current literature, two authors (JAS, RF) constructed a
questionnaire regarding clinical imaging practice, notably
the MR imaging technique used for the indeterminate
adnexal mass. An imaging algorithm and draft manuscript
were developed and discussed at two meetings of the
subcommittee and finalised by the four authors after oral
presentation of an outline proposal at the ESUR 2008
meeting (JAS) and a further literature review.
In this article we present our guidelines, illustrating these
with images of a series of masses which presented to one of
the authors (JAS) in a gynaecological oncology unit as
possible malignant masses and whose characterisation
using US proved difficult.
Basic MR imaging protocol
For the examination there is minimal patient preparation.
Opinions regarding the need for patient fasting are divided
with no supporting evidence. There are, however, data
showing the value of intravenous (IV) smooth muscle
relaxants for improvement in image quality of pelvic MR
imaging [10]. An IV cannula should be left in place in case
IV injection of a gadolinium contrast agent is required.
Imaging should comprise as a minimum:
. AT2-weighted (T2W) sagittal sequence of the pelvis
. A pair of T1-weighted (T1W) and T2W sequences cover-
ing the indeterminate adnexal mass in the same orthogonal
(axial or coronal) plane with similar slice thickness
Evaluation of the uterus on the sagittal sequence is
important to determine the presence and extent of leiomyo-
mata, adenomyosis which may be associated with endome-
triosis of the ovary, and to evaluate for endometrial thickening.
The second pair of sequences allows precise comparison
of the tissue characteristics of the adnexal mass, detail its
anatomic location and suggest its organ of origin. The
choice of which orthogonal plane is used is left to the
discretion and preference of the supervising radiographer/
radiologist. If the mass is noted to lie lateral to the uterus on
the initial sagittal T2W sequence its relationship to the
uterus may be better shown on coronal or coronal oblique
imaging, and if it lies above or behind the uterus on axial or
axial oblique orientated imaging.
It is important to identify both ovaries, if there has not
been prior resection, as definition of two normal ovaries
separate from the mass indicates that the mass is either
uterine, tubal or even non-gynaecological. Identification of
the ovaries may be aided by a T2W sequence angled along
the long axis of the uterine body parallel to the endometrial
stripe, along the ‘ovarian axis’. This is planned from the
T2W sagittal sequence of the pelvis. On this sequence the
ovaries typically lie lateral to the uterine cornua and below
the iliac bifurcation on the pelvic sidewall though there is
variation in their location (Fig. 1).
The algorithmic approach: the decision tree
The decision tree in Fig. 2 divides indeterminate masses
into three groups on the basis of their dominant character-
istic on the basic T1W and T2W sequences. For the
purposes of this algorithm, solid material has similar signal
intensity to muscle on T1-weighted sequences and cyst
contents have similar signal intensity on T2-weighted
sequences to urine. The three categories of mass are:
. T1 ‘bright’ masses containing T1 high signal intensity
. T2 solid masses either with predominant signal similar to
skeletal muscle, T2 ‘dark’ solid masses, or higher than
muscle, T2 ‘intermediate’ or mixed signal solid masses
. Complex cystic or cystic-solid masses
This decision tree directs the selection of additional
problem-solving MR imaging sequences and the diagnostic
process to define the nature of the great majority of
indeterminate adnexal masses and importantly to identify
that minority masses which should be considered probably
or definitely malignant.
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T1 bright mass T2 solid mass  Cystic-solid mass 
 FST1W 
 Signal 
loss  
Remains bright
T2 shading  Mature 
teratoma*
Haemorrhagic 
mass*
Benign stromal 
mass e.g. fibroma
Homogeneous 
T2 dark
CET1W
Tumoral 
enhancement
 oblique T2W
Ovarian Arises from
uterus 
Leiomyoma
T2 
mixed
Malignant
mass 
Inflammatory 
enhancement
Tubo-ovarian 
abscess 
Fig. 2 ESUR decision tree for
MR imaging of the US indeter-
minate adnexal mass. *Note that
any mass with MR features
suggestive of malignancy
should undergo CET1W
imaging
Fig. 1 Use of the ‘ovarian
axis’: a Transvaginal ultraso-
nography (TVUS) image show-
ing an indeterminate solid left
adnexal mass adjacent to the
uterus; b initial sagittal T2-
weighted image of the pelvis
indicating the plane for the
‘ovarian axis’, the long axis of
the uterus, parallel to the endo-
metrial stripe (white line) and c,
d the mass shown to be a T2
‘dark’ solid structure in the left
ovary (arrow) separate from the
uterus, an ovarian fibroma
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The algorithmic approach: additional MR imaging
sequences
Three additional sequences are of value in defining the site of
origin and the nature of the indeterminate mass but for most
masses a single selected problem-solving sequence suffices to
answer the uncertainty of the indeterminate US examination:
. T1 ‘bright’ masses require additional fat-suppressed
T1-weighted (FST1W) imaging using chemical pre-
saturation to distinguish fat in mature teratomas, which
show signal loss becoming ‘dark’ on the FST1W
images, from blood, mucin, other proteinaceous ma-
terial and rarely melanin which remain ‘bright’.
. T2 solid masses may require additional T2-weighted
oblique imaging across the maximum point of contact
of uterus and mass to identify their relationship with
the uterus i.e. distinction of uterine leiomyoma from
ovarian fibroma. Solid ovarian masses with inhomo-
geneous low T2 signal or intermediate T2 signal
require assessment of the degree of gadolinium
enhancement (CET1W).
. All masses with suspected solid elements require gado-
linium-enhanced T1-weighted (CET1W) sequences to
determine the presence of neoplastic tissue. This applies
not only to classic complex cystic and cystic-solid masses
but also to other masses with ‘worrying’ solid compo-
nents. Some mature teratomas and complex endometrio-
mas contain solid elements which should raise concern as
both entities may rarely undergo malignant change.
However, many US indeterminate masses, which are
most commonly haemorrhagic or endometriotic cysts,
atypical dermoid tumours with minimal fat or in the
leiomyoma/fibroma spectrum, can be characterised without
recourse to CET1W imaging. Indeterminate adnexal
masses are summarised by their dominant signal charac-
teristic in Table 1.
T1 ‘bright’ masses
These masses require FST1W imaging using chemical
presaturation to distinguish fat from blood (Figs. 3 and 4).
Table 1 Dominant signal characteristic of indeterminate adnexal
masses
T1 ‘bright’ T2 solid Cystic-solid
Mature teratoma Leiomyoma Cystadenoma
Haemorrhagic cyst Fibroma/thecoma Cystadenofibroma
Endometrioma Struma ovarii Borderline tumour
Mucinous cystadenoma Primary cancer* Primary cancer*
Melanoma metastasis Metastasis Metastasis
Hydrosalpinx
Abscess
*In the first two decades of life primary cancers are most commonly
germ cell or sex cord tumours but in older women are most
commonly epithelial tumours
Fig. 3 T1 ‘bright’ mass on MR imaging after US showing a
complex cyst with a nodular area in its left wall (arrow): a T2-
weighted, b T1-weighted and c corresponding fat-suppressed T1-
weighted image showing complete suppression of the T1 ‘bright’
nodule, a classic mature cystic teratoma with minimal fat. Note on
the T2-weighted image subtle chemical shift artefact at the interface
of fat and water
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The FST1W sequence should be performed in the same
plane as the T1W sequence and with similar parameters to
allow direct comparison. Some foci of fat in teratomas are
very small but these still show distinct signal loss on the
FST1W sequence (Fig. 3).
There are other ‘signature’ appearances of fat and blood
on the standard T1 and T2W sequences. Products of
haemorrhage result in T2* effects (Fig. 4) with dependent
darkening, dependent graded ‘shading’ and even bright-
dark fluid–fluid levels in cysts and/or T2 darkening in the
walls of haemorrhagic cysts [11]. Blood products of
differing ages and such striking sedimentation and
deposition of blood products indicate endometriosis.
Teratomas can have protean appearances. The usual
reason why mature teratomas cannot be confidenetly
diagnosed by US are a minimal fat content and a
predominantly solid nature. The presence of even very
small amounts of fat indicates a mature teratoma (Fig. 3)
but there may also be blood products from prior torsion
of the mass or proteinaceous fluid from glandular
components e.g. with secretions from respiratory or
enteric-type epithelium (Fig. 5). One should not to be
dissuaded from making the diagnosis when there is
demonstrable fat suppression by finding these persistently
‘bright’ areas on the FST1W images. It is important to
look for chemical shift artefact (Figs. 3 and 5) which
may identify very small fatty elements [12]. It is always
important to examine the contralateral ovary carefully for
features of a small teratoma as these are commonly
bilateral (Fig. 5).
If CET1Wimages are obtained there may be enhancement
of mature elements such as skin appendages which may
mimic the features of malignancy. Malignant change in a
mature teratoma is quite rare in adults but should be
suspected with a dominant solid component showing wall
thickening, irregularity or breach. In the childhood/juvenile-
type teratomas a wide variety of immature and malignant
elements may be found. In the older woman with a mature
teratoma malignant change is usually from skin elements to
squamous carcinoma [13].
With haemorrhagic lesions problems may arise in
sonographic distinction of blood clot from a vegetation,
notably when this is adherent to the cyst wall. One
helpful hint that may be apparent by the time the MR
imaging takes place is that the clot has become smaller
as further retraction occurs. This is just one reason why
comparison with the initial US study is necessary. Again,
when there is concern for a solid malignant nodule in a
haemorrhagic mass, it must be regarded as a cystic-solid
mass which requires IV administration of a gadolinium
contrast agent to clarify if the nodule is vascularised
tumour.
Fig. 4 T1 ‘bright’ mass with
MR imaging of haemorrhagic
disease of the ovary: a TVUS
image showing a complex mass
with both hypoechoic and
echogenic nodular areas; b T2-
weighted image showing a left
ovary enlarged by T2 ‘dark’
mass which was persistently
‘bright’ on both the c T1-
weighted and d fat-suppressed
T1-weighted images. Note the
T2 image shows T2* shading in
the dependent portion in keep-
ing with sedimentation of
chronic blood products in an
endometrioma and even on the
T1-weighted images some de-
pendent clot causes signal loss
(arrow)
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T2 solid masses
Solid adnexal masses cause alarm because of concerns for
metastatic malignancy (Table 1). In clinical practice,
however, when dealing with a sonographically solid
indeterminate mass without overt signs of malignancy the
overwhelming likelihood is of a benign mass. Most are
uterine leiomyomata or ovarian fibromata [8]. These are
very ‘dark’ in T2 (and T1) signal when compared with
skeletal muscle, often homogeneously black, smooth and
well-circumscribed (Fig. 1).
For these masses the algorithmic approach advises
oblique T2W imaging through the maximum point of
contact between the mass and the uterus (Fig. 1). An
ovarian fibroma is separate from the uterus and only one
normal ovary is seen, contralaterally (Fig. 1). With an
ovarian fibroma there may be normal remnant ovary
draped around the solid mass or the solid mass may be
exophytic from the ovarian tissue [14].
A pedunculated uterine leiomyoma is attached to the
uterus by a stalk which may contain the ‘bridging vessels’
which supply it. Conversely adnexal masses are usually
supplied from the gonadal pedicle. These signs of vascular
supply may be valuable in further confirming the origin of
the indeterminate mass but are not always present. A
subserosal uterine leiomyoma has normal myometrium
grasping round its margins, the ‘claw’ sign (Fig. 6). A
leiomyoma within the broad ligament is separate from both
the uterus and the ovary on that side.
When there is a homogeneous T2 ‘dark’ solid mass
which has one of these characteristics diagnosis is
completed by use of the oblique T2W sequence when
this defines the connection or otherwise with the uterus or
ovary (Fig. 1).
T2 ‘intermediate’ or mixed signal solid masses have T2
intermediate signal or T2 inhomogeneous signal with a
mixture of T2 dark and bright signal. These may represent
either benign solid masses which have undergone degen-
eration, endocrine active tumours such as thecoma, Leydig
cell or granulosa cell tumour or malignant masses, either
primary or secondary. The last of these is of greater concern
in a woman with a history of a cancer recognised to
metastasise to the ovary e.g. bowel or breast cancer.
Whilst classic T2 ‘dark’ solid masses shown to be
ovarian fibromata do not require further characterisation,
T2 ‘intermediate’ or mixed signal solid masses may require
3Fig. 5 a T2-weighted, b T1-weighted and c corresponding fat-
suppressed T1-weighted (FST1W) image showing incomplete
suppression of the T1 ‘bright’ lesion, a classic mainly cystic
teratoma of the right ovary showing marked internal chemical shift
artefact. There is one locule medially which shows no reduction in
signal on the FST1W image (arrow) which contained blood
products when cut open by the pathologist. Note also small dark
nodules in the left ovary (arrowhead) which were calcified/ossified
elements in a small fat-poor contralateral mature teratoma
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CET1W imaging (Figs. 7 and 8). Concern about a solid
mass may be furthered when there is ascites but this does
not necessarily imply malignancy as it may be seen with
some fibromata (Meig’s syndrome).
After IV injection of gadolinium benign lesions in the
fibrothecoma spectrum show little or no enhancement
(Fig. 7) but solid malignant masses show marked enhance-
ment (Fig. 8). Thus masses with similar T2 signal and
appearances are easily separated into benign or malignant
categories by additional CET1W imaging (Figs. 7 and 8).
The difference in enhancement is usually dramatic. A
minority of our group recommended use of fat-suppressed
CET1W imaging to assess the degree of enhancement
(Fig. 7) but there are no convincing data to support this.
Indeed data are lacking to define just how much enhance-
ment should be considered significant.
Endocrine tumours with functioning stroma are rare.
These more commonly present clinically with hormonal
effects such as hirsutism (Leydig cell tumour) or uterine
oestrogenisation with endometrial thickening or dysfunc-
tion (granulosa cell tumour). Hence these are more often
discovered in a search for the cause of the hormonal
problem than as a sonographically indeterminate mass.
These tumours have a variety of morphological features but
usually show significant enhancement [15].
Some malignant masses are predominantly solid
(Fig. 8). On CET1W imaging these enhance brightly in
their solid components but may show necrosis as the
tumour outgrows its blood supply. Women with solid
malignant masses require referral to a specialist gynaeco-
Fig. 7 Use of CET1W imaging
for a T2 ‘intermediate’ solid
mass: a TVUS image showing a
solid adnexal mass and b sagit-
tal T2-weighted of the pelvis
showing an intermediate signal
inhomogeneous mass (arrow)
separate from the uterine fundus
and small volume ascites in this
post-menopausal woman; c T1-
weighted and d fat-suppressed
contrast-enhanced T1-weighted
image showing minimal en-
hancement (arrowhead) when
compared with the uterus
(arrow). This was a fibroma
with a minimal thecoma element
Fig. 6 T2 ‘dark’ solid mass with oblique T2W MR imaging along
the ‘ovarian axis’ showing a subserosal leiomyoma of the right side
of the uterus (arrow) with a ‘claw’ of normal myometrium grasping
it. Note the normal right ovary lateral to the mass and from which it
is quite separate
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logical oncologist and should undergo further assessment
using contrast-enhanced CT (CECT). With suspected
ovarian cancer CECT of the abdomen and pelvis is
recommended to assess the extent of disease but also to
inspect sites of potential primary tumour in the gastroin-
testinal tract. Some primary epithelial ovarian cancers are
solid but the concern for any solid malignant mass should
also be for a metastasis from sites such as the bowel or
breast (Fig. 8).
Post-menopausal ovaries are now commonly identified
by modern high resolution cross-sectional imaging. It is no
longer true that, if identified by cross-sectional imaging,
post-menopausal ovaries are probably enlarged and thus
abnormal. They are now often seen with high resolution US
and CT. At MR imaging post-menopausal ovaries are
predominantly solid with a stroma which is T2 ‘dark’ in
signal and which may contain small immature follicles.
The solid stroma does not enhance.
The complex cystic or cystic-solid mass
The most common benign masses which fall within this
category are multilocular benign cysts, complex tubal
disease and cystadenofibromata. The most worrying diag-
nosis is ovarian malignancy, either borderline or frankly
invasive cancer.
Purely cystic lesions are benign and do not require
CET1W images, likewise chronic hydrosalpinx, whose
convoluted and opposed folds may cause US findings
which mimic thickened septa. Conversely, acutely tubo-
ovarian masses may produce very complex masses with
wall thickening and ‘pseudo-solid’ areas. These enhance
brilliantly and can mimic malignancy. The clinical features
of acute pelvic infection and malignancy usually differ,
though some chronic infections such as tuberculosis and
actinomycosis may exactly mimic malignancy [16].
The usual cause of an US indeterminate cystic mass is an
area of wall thickening or irregularity. For most cases
simple pre- and post-gadolinium T1W sequences suffice to
evaluate enhancement in nodular mural components
(vegetations) (Fig. 9). Larger solid areas in malignant
masses may show necrosis (Fig. 8) [17, 18]. Enhancement
may be seen in benign cystic-solid lesions in the adeno-
fibroma-cystadenofibroma spectrum (and may correlate
with endocrine activity) but these usually show distinct low
T2 signal [18].
Another option for cystic-solid masses is the use of
dynamic contrast-enhanced MR imaging. This technique
can be ‘temporally bracketed’ between the T1W and
CET1W sequences. Recent data suggest that enhancement
profiles within solid vegetations can help in identifying
3Fig. 8 Use of CET1W imaging for a T2 ‘intermediate’ solid mass: a
sagittal T2-weighted of the pelvis showing an intermediate signal
inhomogeneous mass (arrow) separate from the uterine fundus and
small volume ascites in this post-menopausal woman; b T1-
weighted and c contrast-enhanced T1-weighted image showing
marked enhancement (arrow) with some areas of necrosis within the
solid mass. This was a solitary metastasis from a previously resected
breast cancer
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lesions which require cancer surgery by distinction of
benign from borderline and malignant disease [19].
In some cases the findings of US are highly likely to
represent malignancy but the finding is totally unexpected
e.g. in a very young woman (Fig. 9). Here MR imaging can
be used for secondary confirmation. Even very small foci
of malignancy can be demonstrated by CET1W MR
imaging (Fig. 10).
Practical considerations
The principal strength of this algorithmic approach (Fig. 2)
also points to a practical difficulty. Supervision of the
examination by a radiologist with an interest in gynaeco-
logical imaging may be required to define into which
category to place the mass, which problem-solving
sequences need to be performed and for some cases in
which plane to perform problem-solving sequences. We
recognise that this supervision of pelvic MR imaging
though desirable is not universally available.
We would argue that this application of MR imaging
has such importance in determining clinical management
that it deserves such supervision and should be separated
from routine protocol-driven applications of MR imag-
ing. If this cannot be achieved all the problem-solving
sequences may need to be performed. Nonetheless the
diagnostic discipline of the algorithm should assist in
arriving at a clinically useful answer to the problem.
Experienced MR radiographers/technologists using the
algorithm soon become skilled at recognising the MR
imaging patterns and characteristics of the common
indeterminate masses and in selecting appropriate se-
quence(s) to solve the problem. The MR imaging
protocol is summarised in Table 2 and the decision tree
in Fig. 2.
In principle, an earlier diagnosis of cancer should result
from the use of MR imaging. A commonly used sono-
Fig. 9 CET1W MR imaging of
a small stage IA ovarian cancer:
a referral colour Doppler TVUS
image of a complex cystic-solid
mass with internal blood flow,
an unexpected finding in a 29-
year-old woman considered to
have endometriosis; b sagittal
T2-weighted and axial pre- (c)
and post-contrast (d) T1-
weighted images showing
intense enhancement of the
internal nodules (arrows). After
US a malignant diagnosis was
considered as well as complex
endometriosis but after MR im-
aging discussion fertility sparing
cancer surgery was planned in
this young woman
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graphic strategy for the indeterminate mass has been to
repeat the examination after two or more menstrual cycles
to allow products of haemorrhage, which can mimic solid
tumour, to resolve. With MR imaging this delay of 2 to
3 months can be avoided and the timely diagnosis fits well
within a rapid cancer diagnosis strategy [20].
Summary
Most US indeterminate masses which undergo MR
imaging are complex benign lesions. The intervention
of MR imaging can reduce the number of women
undergoing unnecessary ‘overoperation’ as it allows
identification of benign features that obviate cancer
surgery. Conversely an indeterminate adnexal mass
with abnormal solid enhancing (CET1W) soft tissue
elements should be viewed as a cancer, referred to a
specialist surgeon and undergo staging and further
assessment within a specialist centre. MR imaging
allows discrimination of tiny malignant elements within
ovarian masses (Fig. 10).
MR imaging has maximal impact when CA-125 levels
are normal or only slightly raised (Fig. 10) [8]. It has a
central role in defining management options for women
suspected to have ovarian cancer [21]. It is the most cost-
effective intervention for the sonographically indetermi-
nate adnexal mass with the greatest shift in pre-test
probability [22].
Fig. 10 CET1W MR imaging
of a tiny stage IA borderline
ovarian cancer: a TVUS image
showing a small solid nodule
within the right ovary and b T2-
weighted, c T1-weighted and d
CET1-weighted images show-
ing enhancement of the small
nodule (arrow). This 54-year-
old woman had lower abdomi-
nal discomfort and a slightly
raised CA-125. The TVUS
diagnosis was of follicular
haemorrhage
Table 2 Summary of MR imaging protocol
Patient preparation Intravenous smooth muscle relaxant
Placement of intravenous cannula
Basic MR
sequences
Sagittal T2W of the pelvis
Pair of T1W, T2W through the
indeterminate mass
±T2W sequence in the long axis of the uterus*
Problem-solving
sequences
T1 ‘bright’ mass—FST1W
T2 ‘dark’ solid mass—oblique T2W*
T2 solid mass—CET1W
Cystic-solid mass—CET1W
*In many cases this oblique T2W sequence along the ‘ovarian axis’
suffices (Fig. 1). In other cases a plane selected across the
maximum point of contact of the mass and uterus is required to see
if it is ovarian or uterine in origin
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A small minority of masses will be incorrectly diagnosed
using this algorithmic approach to MR imaging. In series
reported so far these were ‘false positive’ diagnoses of
cancer but this occurred in less than one case in ten [8]. Fat-
poor teratomas, atypical fibromas and cystadenofibromas
[18] continue to confound pre-operative MR imaging
assessment.
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